Merrimack Pharmaceuticals Inc MACK
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if MACK is a good fit for your portfolio.
News
-
Merrimack Receives $225 Million Milestone Payment from Ipsen
-
Merrimack Reports Full Year 2023 Financial Results
-
Merrimack Pharmaceuticals to Get $225 Million Milestone Payment After FDA's Supplemental NDA Approval
-
Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
Trading Information
- Previous Close Price
- $14.68
- Day Range
- $14.67–14.71
- 52-Week Range
- $11.53–15.89
- Bid/Ask
- $14.67 / $14.73
- Market Cap
- $213.33 Mil
- Volume/Avg
- 113,575 / 137,273
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Merrimack Pharmaceuticals Inc is a biotechnology company that discovers, develops, and commercializes innovative medicines that consist of novel therapeutics paired with diagnostics to treat cancer. The company's core approach to systems biology is to apply multidisciplinary capabilities to build functional and predictive computational models of biological systems, such as cell signaling networks. Merrimack also enters into third-party agreements to further process and commercialize its products.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- —
- Website
- https://www.merrimack.com
Comparables
Valuation
|
Metric
|
MACK
|
TYRA
|
ANAB
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 11.24 | 3.09 | 5.99 |
Price/Sales | — | — | 31.12 |
Price/Cash Flow | — | — | — |
Price/Earnings
MACK
TYRA
ANAB
Financial Strength
|
Metric
|
MACK
|
TYRA
|
ANAB
|
|---|---|---|---|
Quick Ratio | 42.80 | 13.27 | 10.62 |
Current Ratio | 43.50 | 13.80 | 10.87 |
Interest Coverage | — | — | −9.09 |
Quick Ratio
MACK
TYRA
ANAB
Profitability
|
Metric
|
MACK
|
TYRA
|
ANAB
|
|---|---|---|---|
Return on Assets (Normalized) | −5.98% | −22.50% | −23.50% |
Return on Equity (Normalized) | −6.13% | −23.73% | −75.96% |
Return on Invested Capital (Normalized) | −9.74% | −27.79% | −68.56% |
Return on Assets
MACK
TYRA
ANAB
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Smgznxjvf | Bfybh | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Xqlzbrcf | Ddhlkd | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Gwfzcsz | Yfqwnr | $98.1 Bil | |
MRNA
| Moderna Inc | Yfqlznp | Ncch | $39.1 Bil | |
ARGX
| argenx SE ADR | Pphqtwf | Rldy | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Bfrpbyqf | Fqn | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Kkbwgznq | Mjkfpf | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Skgdxqd | Jgzwkq | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Ggjxfcgm | Gzzfqvd | $12.5 Bil | |
INCY
| Incyte Corp | Yhjcnrk | Qyvqxkk | $11.9 Bil |